low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
2021-YM-006-02
Phase 2 mab completed
Quick answer
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) for COVID-19 is a Phase 2 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- mab
- Status
- completed